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Background: Transcription factor signal transducer and activator of transcription (STAT) 1 has been linked to a variety
of pathologic states involved with matrix remodeling, but its role in aortic pathology has not been previously described.
The current study hypothesized that STAT1 regulates aneurysmal degeneration and its role was evaluated in human
abdominal aortic aneurysm (AAA) and in a mouse model of aortic dissection.
Methods: Apolipoprotein E knockout mice (ApoE-/-) or ApoE/STAT1 double knockout mice (ApoE/STAT1-/-) were
infused with 1000 ng/kg/min of angiotensin II. Systolic blood pressure (SBP) was measured in the rodent tail. At
sacrifice, aortic diameters and extent of aneurysm formation were measured by digital microscopy. STAT1 and
phosphorylated-STAT1 protein levels were assessed in ApoE-/- mice at 0, 7, 14, and 28 days (n  8/time point) by
enzyme-linked immunosorbent assay. Histology was performed using hematoxylin and eosin (H&E) and Movat stains.
Statistical analyses included 2 test, t test, and analysis of variance.
Results: STAT1 messenger RNA and total protein were greater in human AAA vs non-AAA controls. In addition,
aneurysms occurred in 8%, 50%, and 80% of ApoE-/- mice at 7, 14, and 28 days, respectively. Total STAT1 levels were
not altered during the course of angiotensin II infusion. Phosphorylated STAT1 levels peaked at 7 days with a 1.4-fold
increase over baseline (P < .05). Aneurysms occurred in 0%, 100%, and 100% of ApoE/STAT1-/- mice at 3, 5, and 28
days. In mice infused with angiotensin II for >3 days, aortic rupture occurred more frequently in ApoE/STAT-/- mice
(53% vs 19%, P < .05) and at earlier time points (4.0  0.5 vs 9.2  0.77 days, P < .05) vs ApoE-/- mice. SBP did not
differ between the groups during angiotensin II infusion. By 28 days, aneurysms were larger in ApoE/STAT1-/- mice
compared with ApoE-/- mice (2.7 0.4 vs 1.9 0.1 mm, P< .05) and were more extensive. H&E and Movat stain did
not reveal differences in aortic wall structural content at baseline between ApoE-/- and ApoE/STAT1-/- mice. Both
groups demonstrated equal disorganization in the aneurysmal state.
Conclusions: Phosphorylated STAT1 is elevated during aneurysmal degeneration. Its loss is associated with a higher rate
of acute aortic rupture and more extensive aneurysms in a mouse model of aortic dissection. Further investigation is
necessary to determine whether these observations are secondary to an underlying aortic wall abnormality or alterations
in vessel wall matrix remodeling. (J Vasc Surg 2010;51:951-61.)
Clinical Relevance: Abdominal aortic aneurysms (AAA) are a major health concern. Age, smoking, hypercholesterolemia,
family history of AAA, and atherosclerotic disease all correlate with an increased risk for the development of aortic
aneurysms. Most AAAs remain undetected until the aneurysm presents with a rupture or is identified incidentally.
Currently, the only mode of treatment is operative intervention by conventional or endovascular surgery before
significant aneurysm expansion and rupture. Future improvement in outcomes for patients with aneurysmal disease will
involve the early identification of patients prone to develop AAA and those with small, low-risk aneurysms. Pharmacologic
therapy to prevent aortic wall deterioration and subsequent aneurysm formation in this group would prove extraordinarily
beneficial. A better understanding of the sequence of biochemical and cellular events that lead to AAA formation would allow
the development of pharmacotherapies targeted at preventing aneurysm development and expansion.
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April 2010952 Eagleton et alAbdominal aortic aneurysm (AAA) formation is a mul-
tifactorial process resulting from the altered homeostasis of
aortic wall matrix protein production and destruction.
Multiple mechanisms contribute to the development of
aneurysms. One end point of these mechanisms is the
upregulation of enzymes capable of degrading the extracel-
lular matrix structural proteins. The production of new
matrix proteins by aortic smooth muscle cells is insufficient
to compensate for this, resulting in weakening of the aortic
wall. Pivotal enzymes involved in this process include ma-
trix metalloproteinases (MMPs), plasminogen activators,
and serine elastases.1-3
Although these enzymes are clearly important in aneu-
rysm formation, a growing body of evidence demonstrates
the significance of the proteins involved in regulating their
expression. Inhibition of c-Jun N-terminal kinase, a mitogen-
activated protein kinase, not only prevents experimental
AAA formation but may also cause regression of the aneu-
rysms.4 In addition, inhibition of transcription factors nu-
clear factor-B and ets ameliorate AAA formation in an
experimental animal model.5 In fact, the combined inhibi-
tion of both of these transcription factors has led to the
regression of experimental AAA formation.4
The signal transducer and activator of transcription
(STAT) proteins, a family of transcription factors that exist
as inactive monomers, are phosphorylated, form ho-
modimers or heterodimers, and translocate to the nucleus.
The classic model for STAT activation depends on a series
of tyrosine phosphorylations that are carried out by JAK
proteins, a family of membrane receptor-associated tyrosine
kinases.6 Phosphorylated STATs dimerize, translocate to
the nucleus, and bind to specific gene activation sites,
resulting in induction—or inhibition—of transcription of
downstream target genes.7 Seven STAT family members
have been characterized (STAT-1, -2, -3, -4, -5, -5, -6)
and have been associated with numerous cytokine, growth
factor, and interferon (INF) receptors. In healthy cells, the
activation of STAT proteins is transient, ranging from a few
minutes to a few hours. In disease states, however, consti-
tutive activation of STATs can occur.8
STAT1 is a ubiquitous transcription factor that has,
classically, been associated with IFN signaling, although
other triggers of its activation have been deemed equally
important. STAT1 is activated by phosphorylation of ty-
rosine 701. Alternatively, STAT1 may be phosphorylated
by serine 727 phosphorylation. Tyrosine and serine phos-
phorylation are not interdependent, and STAT1 can be
selectively phosphorylated on tyrosine residues, serine
residues, or both. In addition, STAT1 may form a ho-
modimer, or a heterodimer with phosphorylated STAT2 or
STAT3. The site of phosphorylation, the dimers subse-
quently formed, and the cell and tissue location determine
the downstream specificity of STAT1. Its activation has
been associated with regulation of apoptosis and extracel-
lular matrix regulation, and both processes are important to
aneurysm formation.6 Although recently STAT1 has been
implicated in atherogenesis, its role in aneurysm formation
has not previously been reported.9This current study hypothesized that STAT1 is impor-
tant in aortic aneurysm formation. This study evaluated the
expression of STAT1 in human AAA and in an experimen-
tal murine model of aneurysm formation and evaluated the
significance of this transcription factor in experimental an-
eurysm development.
METHODS
All experiments and procedures were approved by the
Cleveland Clinic Institutional Animal Care and Use Com-
mittee.
Animals. Apolipoprotein E knockout (ApoE null or
ApoE -/-) mice were originally obtained from the Jackson
Laboratory (BarHarbor,Me), while ApoE/STAT1 double
knockout (ApoE/STAT1 null or ApoE/STAT1 -/-) mice
were a generous gift from Dr Chisolm.9 Both strains were
maintained in breeding colonies in the Lerner Research
Institute at Cleveland Clinic. All reagents, unless otherwise
stated, were obtained from Sigma (St. Louis, Mo).
Aortic aneurysm. Human aortic aneurysm tissue was
obtained from 12 patients undergoing surgery for an AAA,
and control aortic tissue was obtained from 9 donors dur-
ing organ procurement. Specimens were snap frozen in
liquid nitrogen and stored at 80°C until further use.
Limited demographic data are available on the healthy
aortic samples and are limited to age, gender, and race.
The study used 95 ApoE null mice, 20 STAT1 null mice,
and 56 ApoE/STAT1 null mice, all were males aged 3 to 6
months, and were fed normal chow diets. Mice underwent
implantation of subcutaneous osmotic minipumps (Model
2004, ALZA Scientific Products, Mountain View, Calif)
under ketamine (150 mg/kg) and xylazine (7.5 mg/kg)
anesthesia. Pumps were filled with a sufficient concentra-
tion of angiotensin II (Ang II) to provide a continuous
infusion of 1000 ng/kg/min for up to 28 days. Mice were
sacrificed at 0, 3, 5, 7, 14, and 28 days (n 8/strain/time
point) of Ang II infusion. In addition, 20 male STAT1 null
mice (Taconic, Hudson, NY), 10 female ApoE null mice,
and 10 female ApoE/STAT1 null mice underwent infusion
of Ang II for 28 days before sacrifice.
Before sacrifice, maximum aortic diameter was mea-
sured using a micrometer. The micrometer was normalized
to a known length (ruler) before each measurement. Aortic
morphology was assessed and assigned to one of the fol-
lowing categories: normal, type I (dilated lumen, no
thrombus), type II (remodeled tissue with intraluminal
thrombus), type III (bulbous form of type II), and type IV
(multiple, diffuse aneurysm with intraluminal thrombus) as
previously described.10 Aneurysms were considered present if
the diameter was 100% greater than corresponding aortic
segments of mice not infused with Ang II.
Indirect systolic blood pressure measurement.
Systolic blood pressures (SBP) were obtained in unanesthe-
tizedmice before pump implantation and again during Ang
II infusion. Mice were acclimated to the restrainer (IITC
Life Sciences, Woodland Hills, Calif) and warming cham-
ber (kept at 31-34°C) for 2 days before these measure-
ments. Pressure measurements were obtained through an
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taken over the course of 10 minutes, as previously de-
scribed.11
Quantitative real-time reverse transcriptase-polymerase
chain reaction. Expression of messenger RNA (mRNA)
levels of ribosomal 18S-rRNA (Hs03003631_g1), Ang II
type 1 receptor (AT1; Mm01166161_m1), human STAT1
(Hs01014001_m1), mouse STAT1 (Mm01257276_g1),
MMP-2 (Mm00439506_m1), and MMP-9 (Mm00600164_
g1) were assayed using quantitative reverse transcriptase-
polymerase chain reaction (RT-PCR) using Taq-man Gene
Expression Assays (Applied Biosystems, Foster City, Calif).
Briefly, aortic tissues were homogenized using TRIzol re-
agent (Invitrogen, Carlsbad, Calif). Messenger RNA was
reverse transcribed, and the resultant complementary DNA
was amplified by Taq Polymerase (Promega, Madison,
Wis). Gene-specific assays were performed and all data were
normalized and analyzed using Applied Biosystems 7500
operating software. Final data are presented as expression of
indicated molecules relative to expression of internal con-
trol probe sets as outlined in the systems instructions for use
(Applied Biosystems).
Protein immunoassay. Aortic protein was extracted
using Cell Lytic-M (Sigma) lysis buffer. Total aortic protein
was determined with the bicinchoninic acid (BCA) protein
assay (Pierce, Rockford, Ill). Human aortic samples were
assayed for STAT1 using immunoblot assay. Briefly, pro-
tein extracts (20 g/lane) were subjected to electrophore-
sis on a 10% Tris-glycine gel (Invitrogen), transferred to a
nitrocellulose membrane, and blocked in 5% milk protein.
Membranes were then incubated with antibodies for STAT1
(1:2000), tyrosine (701)-phosphorylated STAT1 (1:1000),
and serine (727)-phosphorylated STAT1 (1:1000; Cell Sig-
naling Technology, Beverly, Mass), followed by incubation
with horseradish peroxidase-conjugated goat antirabbit im-
munoglobulin G secondary antibody (1:5000) and detection
using enhanced chemiluminescence (ECL) Western blotting
detection kit (Amersham Bioscience, Piscataway, NJ).
Membranes were stripped and reprobed with an anti-
body to -actin (Cell Signaling Technology) and exposed
to AmershamHyperfilm ECL (GEHealthcare). Films were
scanned using an Epson Perfection 3200 Scanner (Epson
America, Long Beach, Calif), and band density was ana-
lyzed using Image J software (National Institutes of
Health, Bethesda, Md). Mouse total STAT1 and active
STAT1 were assayed using a commercially available tran-
scription factor assay (Human/Mouse Active STAT1 p91,
R&D Systems, Minneapolis, Minn) that uses a biotinylated
double-stranded oligonucleotide containing a consensus
STAT1-binding site to capture and measure activated
STAT1 (both tyrosine- and serine-phosphorylated forms).
Substrate gelatin zymography. Protein was isolated
from the aqueous phase of TRIzol extraction and quanti-
tated using the BCA protein assay. Semiquantitative MMP
activity and distribution from harvested aortic protein ex-
tracts was determined by gelatin zymography, as previ-
ously described.12 Briefly, after electrophoretic protein
separation on precast 10% sodium dodecyl sulfate (SDS)-polyacrylamide gels containing 1 mg/mL gelatin (Novex,
San Diego, Calif), proteins were renatured in 2.7% Triton
X-100 for 30 minutes and the gels incubated for 36 hours
at 37°C in 50mMTris-HCl, 5mMCaCl2, and 0.2% Brij35.
After staining with Coomassie blue R-250 and destaining
overnight with 10% acetic acid, gelatinase activity became
evident by clear bands against a dark blue background. The
relative molecular weight of each band was determined by
comparison of the bands against MMP-2 (72 kDa) and
MMP-9 (92 kDa) standards (Oncogene Research Prod-
ucts, Boston, Mass). MMP activity was measured by stan-
dard densitometry techniques, as described above.
Histologic and immunohistochemical analysis. Aortic
samples, at the time of harvest, were placed in 10% buffered
formalin for 24 hours, followed by reagent alcohol (70%
volume/volume) for subsequent permanent section after
being embedded in paraffin. After deparaffinization, aortic
sections were stained with hematoxylin and eosin. In addi-
tion, to further assess collagen distribution, samples were
stained with Brillmeyer’s trichrome stain.
After deparaffinization, samples were placed in hema-
toxylin for 40 seconds, followed by 0.2% (weight/volume)
acid fuchsin for 1 minute. This was followed by a 3-hour
incubation at room temperature in 0.5% aniline blue, 2%
orange G, and 1% phosphomolybdic acid in 100% ethanol.
Movat stain was performed on deparaffinized aortic sec-
tions. Samples were placed in 1% Alcian blue for 20 min-
utes, washed with water, and placed in alkaline alcohol at
56°C for 10 minutes. This was followed by serial exposure
toOrcein-Verhoeff solution, woodstain scarlet-acid fuchsin
solution, 0.5% acetic acid, 5% phosphotungstic acid, 100%
ethyl alcohol, alcoholic saffron, and ultimately, xylene.
For immunohistochemistry, tissue sections were depar-
affinized and dehydrated through graded xylene and etha-
nol. For antigen retrieval, slides were incubated in the
microwave for 20minutes in 0.01mol/L citrate buffer, pH
6 (Fisher Scientific). To block endogenous peroxidase, the
slides were incubated in 3% H2O2 for 10 minutes at room
temperature. Nonspecific binding was blocked by incuba-
tion with 5% normal goat serum for 30 minutes at room
temperature. Incubation was performed with 1:50 rabbit
polyclonal to STAT1 (phosphoY701; Abcam Inc, Cam-
bridge, Mass) and STAT1 (phosphoS727; Abcam).
Slides were rinsed in phosphate-buffered saline (PBS)-
0.1% Tween 20 and incubated in antirabbit biotinylated
secondary antibody (1:4000 dilution, Vector Laboratories,
Burlingame, Calif) for 30 minutes, followed by incubation
with Vectastain ABC Reagent (Vector Laboratories) for 30
minutes at room temperature. Immunoreactive cells were
then visualized by the addition of diaminobenzidine (Vec-
tor Laboratories) and counterstained with hematoxylin.
Cholesterol and lipoprotein levels. Blood was col-
lected from mice at the time of sacrifice and plasma was
isolated. Plasma samples were diluted 2:1 with a solution
containing 500 mmol/L MgCl2 and 10 g/L dextran sul-
fate. After precipitation at room temperature for 10 min-
utes, the reaction mixture was centrifuged at 1500g for 30
minutes at 4°C, and the supernatant was collected for
rysm
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precipitate was resuspended in 75 L of Dulbecco’s PBS
for determination of low-density lipoprotein (LDL) and
very-LDL. Total cholesterol was determined by directly
assaying 10 L of plasma. Thermotrace Cholesterol Re-
agent was added to the samples and allowed to sit for 15
minutes at room temperature.
Spectrophotometric measurements were made at 500
nm. Final values were obtained by plotting the optical
density of the unknown samples on standard curves with
cholesterol standards.
Statistical analysis. Data were analyzed using non-
paired t test and analysis of variance. Significance was set at
P .05. Analysis was performed using JMP 6.0.3 software
(SAS Institute Inc, Cary, NC). Results are expressed as
mean 	 standard error of the mean.
RESULTS
The cohort that provided the AAA tissue samples was
older (mean age, 75.7	 2.8 years) and hadmoremen (80%
men) than the donors of the nonaneurysmal tissue (mean
age, 37.6 	 5.7 years; 60% men). STAT1 mRNA levels
were 1.87-fold greater in AAA tissue compared with non-
aneurysmal controls (P  .05). A 72% increase in total
Fig 1. A, Representative immunoblots show the asses
activator of transcription 1 (STAT1) from human aortic h
and those without aneurysms (NA). -actin was also ass
STAT1 in the tyrosine- and serine-phosphorylated form.
the different phosphorylated forms, there was a significan
aortic aneurysm (AAA, grey bars) vs those without aneuSTAT1 protein (P .01) was observed in aneurysmal tissue(Fig 1), but no increase was noted in the fraction of STAT1
in the tyrosine- or serine-phosphorylated forms. When
normalized to total protein, there was a trend toward
elevated tyrosine-phosphorylated STAT1, but this did not
reach statistical significance.
To gain further insight into STAT1 alterations during
aortic aneurysm formation, STAT1 expression was evalu-
ated during the process of experimental aortic aneurysm
formation in the Ang II infusion model of aneurysm for-
mation. Aneurysm formation occurred in 0%, 12.5%, 50%,
and 87.5% of ApoE null mice infused with Ang II for 0, 7,
14, and 28 days, respectively (n  8/time point). During
the first 14 days, there was a trend towards decreased total
STAT1 protein levels, but a significant increase occurred in
the fraction of STAT1 in the active form (P  .05; Fig 2).
Although changes were noted in STAT1 protein levels
and STAT1 activation, no temporal changes occurred in
STAT1 mRNA during Ang II infusion or when compared
with baseline levels. As has been previously described,
histologic evaluation of the aorta at this time point demon-
strates the presence of an aortic dissection (Fig 3).13
Immunohistochemical analysis for tyrosine-phosphorylated
STAT1 demonstrated its presence in the inflammatory cells
infiltrating the false lumen of the aortic dissection, but its
t of tyrosine-, serine-, and total signal transducer and
genates in those with abdominal aortic aneurysm (AAA)
in these samples. B, Graph demonstrates the fraction of
ough there were no changes in the fraction of STAT1 in
ease in total STAT1 protein from those with abdominal
(NA, black bars; *P  .05).smen
omo
ayed
Alth
t incrpresence was void from the regions adjacent to the true
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STAT1 did not reveal any serine-phosphorylated staining at
baseline or during the course of Ang II infusion.
Aortic aneurysm formation did not occur in STAT1
null mice infused with Ang II, but they did occur in
ApoE/STAT1 null mice, with 100% of the mice develop-
ing aortic aneurysm by 3 days of Ang II infusion. By 28 days
of Ang II infusion, aortic aneurysms were larger in the
ApoE/STAT1 null mice compared with the ApoE null
mice (2.7 	 0.4 vs 1.9 	 0.1 mm; P  .05; Fig 4).
All of the aneurysms that occurred in the ApoE/
STAT1 null mice were of the type IV morphology, whereas
this occurred in only 12.5% of the ApoE null mice, which
were predominantly the type III morphology (75%; Fig 4).
In fact, the aneurysm in ApoE/STAT1 null mice typically
extended from the left subclavian artery to the aortic bifur-
cation.
Aortic rupture was more frequent in ApoE/STAT1
null mice, occurring in 53% of ApoE/STAT1 null mice
infused with Ang II for 
3 days and in 81% of these mice
infused for
5 days. Aortic rupture occurred in only 20% of
ApoE null mice. Aortic rupture occurred earlier in ApoE/
STAT1 null mice (4.0 	 0.5 days) compared with ApoE
null mice (9.2 	 0.8 days, P  .05).
Gender proved to be protective against aneurysm for-
mation: no aneurysms were formed in the female ApoE null
mice or ApoE/STAT1 double-null mice in response to 28
days of Ang II infusion (Fig 4). Baseline SBP did not differ
significantly between ApoE/STAT1 null mice and ApoE
null mice, and both groups responded with a similar in-
crease in blood pressure in response to the Ang II infusion
(13 	 3 mm Hg increase and 14 	 6 mm Hg increase,
respectively).
Baseline histologic evaluation of the aortic walls from
ApoE/STAT1 null and ApoE null mice demonstrated no
difference in the aortic wall architecture (Fig 5). In addi-
Fig 2. Graph presents temporal changes in aortic total signal trans-
ducer and activator of transcription 1 (STAT1) protein (black bars)
and activated STAT1 protein (grey bars) and STAT1messenger RNA
from mice undergoing angiotensin (Ang) II infusion (n  8/time
point). Changes are normalized to baseline aortic levels. Although
there was a trend in a decrease in total STAT1 during the first 2 weeks
ofAng II infusion, this did not reach statistical significance.Therewas,
however, a significant increase in the fraction of STAT1 in the active
form (both serine- and tyrosine-phosphorylated STAT1), peaking at
7 days of Ang II infusion (*P .01).tion, baseline expression of MMP-2 and MMP-9, based onFig 3. Representative immunohistochemical analysis of an apoli-
poprotein E null mouse aorta harvested at 7 days of angiotensin II
infusion. A, At 7 days there is evidence of an aortic dissection with a
false lumen (FL) and patent true lumen (TL; original magnification
20). Immunohistochemical staining for tyrosine-phosphorylated
signal transducer and activator of transcription 1 (STAT1) was per-
formed, and regions of the aorta bordering the false lumen (B) and
the true lumen (C) were evaluated under higher magnification
(original magnification100). B, Inflammatory cells infiltrating the
false lumen (FL) stain positively (arrow) for tyrosine-phosphorylated
STAT1. C, No positive staining is observed along the true
lumen (TL) border.
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activator of transcription 1 (STAT1)-/-, and ApoE/STAT1-/- mice after 28 days of angiotensin (Ang) II infusion. No
significant aortic enlargements observed in STAT1-/-malemice or in any of the femalemice strains after 28 days of Ang
II infusion. Aortic enlargement was observed in male ApoE-/- and male ApoE/STAT1-/- mice, and was larger in the
ApoE/STAT1-/- mice compared with the ApoE-/- mice (*P .05). B,Graph presents aortic aneurysm morphology
identified in ApoE-/- male mice (black bars) and ApoE/STAT1-/- male mice (clear bars). All ApoE/STAT1 null mice
developed the type IV phenotype. C, Examples of aortas resected from (a) an ApoE-/- mouse that did not undergo
Ang II infusion, (b) an ApoE-/- mouse that developed a type II morphology aneurysm, and (c) an ApoE/STAT1-/-
mouse that developed a type IV morphology aneurysm. The upward pointing arrows in all three instances denote the
location of the right renal artery, and the block triangles point to locations of aneurysmal degeneration (only b and c).
n are
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tin zymography, did not differ between the two strains of
mice (Fig 6). When evaluated by gelatin zymography after
28 days of Ang II infusion, totalMMP-2 andMMP-9 levels
were 1.9-fold and 2.7-fold, respectively, higher than base-
line levels in ApoE null mice, 1.8-fold and 2.9-fold higher
than baseline levels in ApoE/STAT1 double-null mice (Fig
6), but only 0.9-fold and 1.1-fold different than baseline in
STAT1 null mice. Furthermore, relative Ang II type I
receptor mRNA expression did not differ significantly be-
tween the ApoE null mice and ApoE/STAT1 null mice
(1.0 	 0.5 vs 0.6 	 0.5, respectively; P  .9).
Total cholesterol levels were greater in the ApoE/
STAT1 null mice (333	 59mg/dL) compared with ApoE
null mice (250 	 48 mg/dL, P  .05; Fig 7). The HDL
and LDL fractions, however, did not differ significantly
between the two groups.
DISCUSSION
The aim of this study was to evaluate the potential role
of STAT1 in aortic aneurysm formation. There is limited
information regarding the role of STAT proteins in human
AAA formation. The only previously available information
was the result of gene expression profiling of aortic aneu-
rysm tissue, which demonstrated STAT1 mRNA was up-
regulated in human AAAs compared with non-AAA con-
trols.14 Our human data correlate with these findings and
further demonstrate alterations in STAT1 protein produc-
tion and activation. The human results from our analysis,
however, need to be evaluated with caution. The patient
Fig 5. Representative sections of histologic analysis of
content with trichrome stain from the aortic walls of (A,
of transcription 1 (STAT1) null mice and (B, D) ApoE
elastic lamellae, elastin deposition, or collagen depositiopopulation from which aortic tissue was procured wasyounger and had a higher percentage of women compared
with those with aneurysmal disease. Because of this, we
were not able to determine if the differences in STAT1
expression and activation are only due to the presence of an
aneurysm or if other factors are involved. We were not able
to control for medications, other comorbidities, or the
presence of any significant atherosclerosis, all of which can
alter the expression and activation of STAT1.
These confounding variables, however, are controlled
for in the animal model. Although there is no increased
STAT1 mRNA or total protein in the Ang II infusion
mouse model, STAT1 activation precedes aneurysmal de-
generation. It does, however, appear to temporally be
associated with the histologic presence of the aortic dissec-
tion. In addition, STAT1 may have a protective effect on
the development of aortic dissection and subsequent aneu-
rysmal degeneration, because depletion of STAT1 is asso-
ciated with earlier aneurysm formation, larger and more
extensive aneurysmal degeneration, and a higher rate of
aortic rupture.
The currentmodel depends on the infusion of Ang II in
a hypercholesterolemic mouse. It differs from other mouse
models of aneurysm formation because it does not depend
on the direct application of calcium-chloride or porcine
pancreatic elastase to the aorta.1,15 It also differs from these
models because the aneurysm that forms is more consistent
with the degeneration of an acute aortic dissection that
develops in response to the Ang II infusion. We are unable
to determine from our observations whether the aortic
) elastin content with Movat stain and (B, D) collagen
polipoprotein E (ApoE)/signal transducer and activator
mice (original magnification 100). No differences in
seen at baseline between these two mouse strains.(A, B
C) a
nullruptures that occur are due to profound accelerated aneu-
pond
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aortic wall from the aortic dissection.
The mechanisms by which these pathologies occur are
not clear from the current information. The difference
observed between the ApoE/STAT1 null mice and STAT1
Fig 6. A, Representative gelatin zymograms from ao
transducer and activator of transcription (STAT1)-/-,
angiotensin (Ang) II infusion. The 92 kDa protein corre
kDa protein corresponds to pro-MMP-2. B, Graphic sho
bars) and ApoE/STAT1-/- (grey bars) mice at baselin
polymerase chain reaction (n  5 mice/strain). Results a
no significant difference in MMP activity or messenger
MMP-2 and MMP-9 activity (assessed by gelatin zymo
(black bars), ApoE/STAT1-/- (gray bars), and STAT
mice/strain). Results are expressed normalized to corresnull mice might have multiple causes. The findings areindependent of the hypertensive effects of the Ang II
infusion. There are equivalent SBPs in the ApoE-/- and
ApoE/STAT1-/- mice, and both strains respond equally
with regard to elevation of SBP pressure with the Ang II
infusion. Hypercholesteremia is more significant in the
omogenates from apolipoprotein E (ApoE)-/-, signal
ApoE/STAT1-/- mice at baseline or after 8 days of
s to pro-matrix metalloproteinase (MMP)-9 and the 72
tal MMP-2 and MMP-9 expression in ApoE -/- (black
ssed by gelatin zymography and reverse transcriptase-
pressed relative to expression in ApoE-/- mice. There is
levels at baseline in these strains. C, Graph represents
hy) from aortic homogenates obtained from ApoE-/-
(white bars) after 28 days of Ang II infusion (n  5
ing strains at baseline.rtic h
and
spond
ws to
e asse
re ex
RNA
grap
1-/-ApoE/STAT1mice, and this difference can be accentuated
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yet to test whether rates of aneurysm formation is altered in
ApoE/STAT1-/- mice fed a high cholesterol diet. We have
determined, however, that no alteration in aneurysm for-
mation occurs in response to the Ang II infusion in
C57Bl/6J mice that are fed a variety of high cholesterol
diets (data not shown).
Interestingly, despite the higher total cholesterol levels,
the loss of STAT1 was associated with diminished area of
aortic atherosclerotic lesion formation.9 These findings fur-
ther support the hypothesis that aortic aneurysm pathogen-
esis is a process that occurs independent of atherosclerosis.
We have previously demonstrated that hypercholesterolemic
mice (ApoE null mice) have significantly elevated AT1 recep-
tor expression compared with normal-cholesterolemic con-
trols.11 This may explain the increased responsiveness of
hypercholesterolemic mice to the Ang II infusion with
aortic aneurysm formation.16,17 It does not, however, ex-
plain the difference between ApoE/STAT1 null mice and
ApoE null mice because baseline aortic AT1 receptor ex-
pression did not differ between theses two strains.
The influence of STAT1 on the development of more
severe hypercholesterolemia is not known. STAT1, how-
ever, is one of the downstream effectors of IFN, which is
known to promote a variety of proatherogenic effects
through multiple mechanisms. In fact, evaluation of
ApoE-/- mice crossed with IFN receptor-/- mice display
a reduction in atherosclerotic lesion size and lipid accumu-
lation.18 Alterations in lipid metabolism were noted in
these mice as well as a significant increase in the distinct
population of lipoprotein particles that are rich in Apo
A-IV, phospholipid, and free cholesterol. The mechanisms
leading to these effects, however, are not known.
IFN has been implicated in aortic aneurysm forma-
tion. Xiong et al19 demonstrated that targeted deletion of
IFN altered MMP expression and ameliorated aneurysm
formation in a calcium-chloride model of aneurysm
Fig 7. Graph shows total cholesterol, low-density lipoprotein
(LDL), and high-density lipoprotein (HDL) from apolipoprotein
E (ApoE) null mice and ApoE/signal transducer and activator of
transcription (STAT1) double-null mice. Total cholesterol levels
are higher in the ApoE/STAT1 double-null mice compared with
ApoE null mice (*P  .04). HDL and LDL levels did not differ
between these two mouse strains.formation. Alternatively, however, Libby et al20 demon-strate that deletion of IFN led to increased expression of
MMP-2 and MMP-9 and more severe aneurysm formation
in an alternate murine model of aortic aneurysm formation.
These latter findings are more consistent with the observa-
tions in our current study. It may be, however, that the
disparity observed in the effects of IFN is due to the
differences in the model of aneurysm formation.
Aside from the Xiong data, a growing body of work
demonstrates that loss of IFN or STAT1 (a downstream
mediator of IFN) is associated with decreased atheroscle-
rotic lesions and with more accentuated aneurysm forma-
tion. These data further support the hypothesis that aneu-
rysm formation is a process that occurs independently of
the development of atherosclerosis. It may be, however,
that the effects of the loss of STAT1 do not directly mirror
those of IFN deletion, because STAT1 is not the only
downstream mediator of IFN signaling nor is IFN the
only promoter of STAT1 activation.
An alternate possibility is that the deletion of STAT1
has altered the baseline structural composition of the aorta.
We did not, however, observe alterations in aortic wall
collagen or elastin composition between the ApoE/STAT1
null and ApoE null strains. These observations were only
made on nonspecific histologic evaluations, and more spe-
cific analysis of collagen, elastin, and other aortic structural
components is necessary. Previous work has demonstrated,
however, that the loss of STAT1is associated with a more
severe fibroproliferative response in a mouse model of lung
fibrosis.21 This response was associated with an increase in
total lung collagen content and enhanced fibroblast prolif-
eration. Interestingly, the loss of STAT1 in this model was
associated with increased activation of STAT3, which has
been associated with interleukin-6 signaling, cell prolifera-
tion, and MMP-2 expression. The loss of STAT1 alone,
however, is not sufficient to explain our findings in the
ApoE/STAT1 null mice because STAT1 null mice (ApoE
competent) did not form aneurysms in response to the Ang
II infusion.
In addition to altering the baseline composition of the
aortic wall, the loss of STAT1 may be associated with
altered expression of enzymes capable of degrading the
aortic wall. The STAT1 pathway has been implicated in the
expression of MMPs. Lentivirus infection of neural tissue
promotes MMP-2 and MMP-9 expression and STAT1
activation.22 Treatment of these neural cells with fludara-
bine, a pharmacologic STAT1 inhibitor, blocked the in-
creasedMMP-2 expression but notMMP-9. Conversely, in
STAT1 null fibrosarcoma tumor cells placed in an in vivo
model of tumor growth, MMP-2 and MMP-9 expression
could be suppressed by the reconstitution of STAT1.23 The
results of these two studies demonstrate that in different
cell lines, a specific STAT may have a different effect on the
expression of a target protein; for example, MMP2 produc-
tion in neural cells was STAT1-dependent, whereas
MMP-2 production in fibrosarcoma cells was inhibited by
STAT1.
The baseline expression of MMP-2 and MMP-9 were
not different between ApoE/STAT1 null mice and ApoE
JOURNAL OF VASCULAR SURGERY
April 2010960 Eagleton et alnull mice. In addition, the changes in MMP levels in
response to Ang II infusion in both groups of mice were
similar. Furthermore, STAT1 mice, which did not form
aneurysms, did not have alterations in aortic MMP-2 or
MMP-9 levels as assessed by gelatin zymography. This may
suggest that alterations in STAT1 do not lead to alterations
in MMP expression, at least in response to Ang II infusion.
Ang II, however, is known to cause a rapid, yet transient,
increase in tyrosine-phosphorylated STAT124,25 and is
known to induce expression of MMP-2 and MMP-9.26,27
In addition, Ang II-dependent STAT1 activation and
MMP expression are temporally associated.28 Our in vivo
evaluation, however, has many variables that cannot be
controlled for. Further evaluation in vitro is warranted to
better define the mechanisms involved in STAT-regulated
MMP expression.
This current study again highlights the findings that
female gender is protective against the development of
aortic aneurysm formation. None of the ApoE/STAT1 null
or ApoE null mice developed aneurysmal degeneration of the
aorta with Ang II infusion. Low rates of aneurysm formation
in this model have been previously described.29,30 These
findings are not unique to this mouse model of aneurysm
formation but have been described in alternate aortic aneu-
rysm mouse models.31 More intensive investigations are
necessary to determine why female gender is protective
against aneurysm formation, but this was beyond the scope
of our study.
CONCLUSIONS
STAT1 appears to have an important role in aortic wall
homeostasis and appears to be protective against the devel-
opment of aortic dissection and aortic aneurysm degener-
ation. Further evaluations of the mechanisms that STAT1
may be affecting that contribute to this protective role are
necessary and underway. A better understanding of the
mechanisms contributing to aortic aneurysm formation is
necessary to develop pharmacotherapies to aid in the treat-
ment of this complex disease process. In addition, the
ApoE/STAT 1 null mouse may provide an excellent model
with which to study alterations that occur during acute
aortic dissection.
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Dr Ronald Dalman (Palo Alto, Calif). If I understand your
presentation correctly, it looks like STAT [signal transducer and
activator of transcription] expression is protective against aneu-
rysm progression; the double knockout seems to increase the rate
of enlargement. This seems somewhat contradictory to the hy-
pothesis that led you to explore this mechanism in the first place.
Perhaps you can comment on this apparent discrepancy?
DrMatthew J. Eagleton. Absolutely. When I started initially
evaluating STAT1,my hypothesis was that loss of STAT1would be
associated with aneurysm inhibition. That hypothesis proved to be
false and the opposite to be true. Some of our cellular work, not
presented here, demonstrates that if we inhibit STAT1 in smooth
muscle cells and macrophages, we see increased MMP [matrix
metalloproteinase] expression and activity in those cells in response
to stimulation, and so STAT1 may have a protective role in some
way by inhibiting MMP expression.
I am not sure though in this model if it is just through
regulation of MMP expression that STAT1 is working. I am
concerned with the acuity with which the dissections occur, and we
are considering that there may be some architectural alteration in
the aortic wall associated with the loss of STAT1. We have not,
however, been able to identify that alteration that would make the
aorta in these double knockout mice more susceptible to an aortic
dissection.
Dr Dalman. Do you use a normal chow diet or a high-fat
chow diet?
Dr Eagleton. These mice are all on a normal chow diet.
Dr Dalman. And the cellularity; is there a difference at all in
the inflammatory cell infiltrate (macrophages/neutrophils) thatDr Eagleton. We have not yet done the morphometric anal-
ysis to look at cell numbers.
Dr Anton Sidawy (Washington, DC). The STATs are tran-
scription activators that get phosphorylated in the cytoplasm but
then move to the nucleus to exert their effect on the gene. Are
there any published data that indicate that this process can get
altered leading to formation of aneurysms in human?
Dr Eagleton. Not in humans. Most of the work done in
humans to date, except for one article that begins to investigate its
role in atherosclerosis, has been done in tumor biology.
Dr Sidawy. And why the female gender is protective?
Dr Eagleton. It’s a great question and I don’t know.
Dr B. Timothy Baxter (Omaha, Neb). One of the things
about the animal models is that findings may be irrelevant to our
patients. You started with the patient tissue, you found a protein of
interest, and then looked at an animal model to see what this
protein is doing. And you found out it was doing something quite
different than what you thought. Beginning with human tissue is
essential to assure relevance of work done in animal models. So I
want to congratulate you on that. We now know that there are
many gene knockout mice that don’t get aneurysms. So my ques-
tion is how are we going to find out which of these proteins are
really critical?
Dr Eagleton. Great question. I think what we may ultimately
have to do is look at a number of these knockout mice, perhaps do
an array analysis on them, and see if there are any downstream
effects that are similar between all of the mice that don’t form
aneurysms and is there a distal common pathway, or pathways, that
are being affected and perhaps that is the area that needs to be
focused on, or several pathways that need to be focused on.
